Literature DB >> 24666672

The roles of traditional Chinese medicine in gene therapy.

Chang-quan Ling1, Li-na Wang2, Yuan Wang2, Yuan-hui Zhang2, Zi-fei Yin2, Meng Wang2, Chen Ling3.   

Abstract

The field of gene therapy has been increasingly studied in the last four decades, and its clinical application has become a reality in the last 15 years. Traditional Chinese medicine (TCM), an important component of complementary and alternative medicine, has evolved over thousands of years with its own unique system of theories, diagnostics and therapies. TCM is well-known for its various roles in preventing and treating infectious and chronic diseases, and its usage in other modern clinical practice. However, whether TCM can be applied alongside gene therapy is a topic that has not been systematically examined. Here we provide an overview of TCM theories in relation to gene therapy. We believe that TCM theories are congruent with some principles of gene therapy. TCM-derived drugs may also act as gene therapy vehicles, therapeutic genes, synergistic therapeutic treatments, and as co-administrated drugs to reduce side effects. We also discuss in this review some possible approaches to combine TCM and gene therapy.

Entities:  

Mesh:

Year:  2014        PMID: 24666672     DOI: 10.1016/S2095-4964(14)60019-4

Source DB:  PubMed          Journal:  J Integr Med


  32 in total

Review 1.  The application status of Chinese herbal medicine in military health service in China.

Authors:  Ge-Liang Yang; Wei Gu; Hui-Qing Zhang; Xiao-Feng Zhai; Xiao-Qian Li; Chang-Quan Ling
Journal:  Chin J Integr Med       Date:  2015-08-11       Impact factor: 1.978

2.  Productive life cycle of adeno-associated virus serotype 2 in the complete absence of a conventional polyadenylation signal.

Authors:  Lina Wang; Zifei Yin; Yuan Wang; Yuan Lu; Daniel Zhang; Arun Srivastava; Changquan Ling; George V Aslanidi; Chen Ling
Journal:  J Gen Virol       Date:  2015-06-30       Impact factor: 3.891

3.  Add-On therapy with Chinese herb medicine Bo-Er-Ning capsule (BENC) improves outcomes of gastric cancer patients: a randomized clinical trial followed with bioinformatics-assisted mechanism study.

Authors:  Boyu Pan; Jingyuan Zang; Jie He; Zhen Wang; Liren Liu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

4.  Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients.

Authors:  Yueh-Hsiang Liao; Chia-Ing Li; Cheng-Chieh Lin; Jaung-Geng Lin; Jen-Huai Chiang; Tsai-Chung Li
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-12       Impact factor: 4.553

5.  Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model.

Authors:  Chen Ling; Yuan Wang; Yuanhui Zhang; Anila Ejjigani; Zifei Yin; Yuan Lu; Lina Wang; Meng Wang; Jun Li; Zhongbo Hu; George V Aslanidi; Li Zhong; Guangping Gao; Arun Srivastava; Changquan Ling
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

6.  Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo.

Authors:  Chen Ling; Yuan Wang; Yuan Lu; Lina Wang; Giridhara R Jayandharan; George V Aslanidi; Baozheng Li; Binbin Cheng; Wenqin Ma; Thomas Lentz; Changquan Ling; Xiao Xiao; R Jude Samulski; Nicholas Muzyczka; Arun Srivastava
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

7.  Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma.

Authors:  Chun-Yu Qian; Kai-Li Wang; Fan-Fu Fang; Wei Gu; Feng Huang; Fu-Zhe Wang; Bai Li; Li-Na Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.

Authors:  Munjal Pandya; Kellee Britt; Brad Hoffman; Chen Ling; George V Aslanidi
Journal:  J Immunother       Date:  2015-09       Impact factor: 4.456

9.  Evaluation of a topical herbal agent for the promotion of bone healing.

Authors:  Wing-Sum Siu; Chun-Hay Ko; Ka-Wing Lam; Elaine Wat; Wai-Ting Shum; Clara Bik-San Lau; Kam-Ming Ko; Leung-Kim Hung; David Tai-Wai Lau; Ping-Chung Leung
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-25       Impact factor: 2.629

10.  Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.

Authors:  Ming-Juan Liao; Mei-Na Ye; Rui-Juan Zhou; Jia-Yu Sheng; Hong-Feng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-10-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.